Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #101 to #150.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Pending further clinical trials‏‎ (2 links)
  2. Pending further clinical trials and data‏‎ (2 links)
  3. Pending review of recent clinical trials and comparative studies‏‎ (2 links)
  4. Phase 3‏‎ (2 links)
  5. Phase III‏‎ (2 links)
  6. Phase III ACT IV trial did not show a significant increase in OS; however, a Phase II trial (ReACT) in recurrent GBM showed improved outcomes with bevacizumab‏‎ (2 links)
  7. Phase II trial showed a significant improvement in PFS, particularly for HLA-A2 positive patients with methylated MGMT, showing a median PFS of 24.1 months vs. 8.5 months in the control group.‏‎ (2 links)
  8. Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27%‏‎ (2 links)
  9. Preclinical studies‏‎ (2 links)
  10. Preclinical studies and early clinical trials‏‎ (2 links)
  11. Proton Pump Inhibitors (e.g., Lansoprazole, Nexium)‏‎ (2 links)
  12. Radiation dermatitis, temporary alopecia, radiation otitis, radiation necrosis (more prevalent in PBT group)‏‎ (2 links)
  13. Ranges from 26 to 44% with different schedules; 61% PFS-6 with the best results obtained using a specific dosing schedule‏‎ (2 links)
  14. ReACT trial showed a 6-month PFS of 28% for the rindopepimut group compared to 16% for the control‏‎ (2 links)
  15. Recent meta-analyses suggest potential for improving cancer treatment outcomes‏‎ (2 links)
  16. SL-701 (Immunotherapy Vaccine)‏‎ (2 links)
  17. Shows a clinically meaningful extension of survival in both newly diagnosed and recurrent GBM patients. Offers fresh hope by potentially improving outcomes in a challenging treatment landscape.‏‎ (2 links)
  18. Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers‏‎ (2 links)
  19. Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments‏‎ (2 links)
  20. Stage 1 median overall survival was 11.0 months with a 12-month OS rate of 44%. Stage 2 showed a median OS of 11.7 months with a 12-month OS rate of 50%, suggesting an improvement over historical data.‏‎ (2 links)
  21. Standard radiation therapy PFS rates are lower compared to PBT‏‎ (2 links)
  22. Standard treatments for GBM typically result in a median overall survival of 14-17 months‏‎ (2 links)
  23. Standard treatments offer a median PFS of about 6.9 months‏‎ (2 links)
  24. Standard treatments offer a median progression-free survival of about 6.9 months.‏‎ (2 links)
  25. The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone‏‎ (2 links)
  26. The vaccine shows promise, especially in extending progression-free survival in newly diagnosed GBM. It offers a novel approach by leveraging the patient's immune system, potentially improving outcomes in a disease with few effective treatments.‏‎ (2 links)
  27. Typically, tumors recur within 6 months of standard treatment.‏‎ (2 links)
  28. Typically around 6-7 months for standard GBM treatments.‏‎ (2 links)
  29. Under investigation; early results promising, especially in combination therapies‏‎ (2 links)
  30. Valganciclovir (Valcyte)‏‎ (2 links)
  31. Valproic Acid/Sodium Valproate (Depakote)‏‎ (2 links)
  32. Variable across studies‏‎ (2 links)
  33. Varied; one study showed median OS of 41.1 months with vaccine and temozolomide, and another indicated 30.3 months with vaccine and basiliximod.‏‎ (2 links)
  34. Varies; can include fatigue, headache, localized reactions at infusion site‏‎ (2 links)
  35. Varies; earlier phases showed median overall survival up to 38 months in phase I trial participants.‏‎ (2 links)
  36. While initial phase III trial results in newly diagnosed GBM were disappointing, the ReACT trial for recurrent GBM suggests potential benefits, particularly when combined with bevacizumab‏‎ (2 links)
  37. Wilms Tumor Peptide Vaccine‏‎ (2 links)
  38. Property:Has Usefulness Explanation‏‎ (2 links)
  39. 13.5 months for general cases, 19.5 months for patients with MGMT methylated tumors.‏‎ (1 link)
  40. 17.8 months for newly diagnosed GBM, possibly the longest PFS seen in a phase II trial for GBM‏‎ (1 link)
  41. 17 months for general cases, 25.5 months for patients with MGMT methylated tumors when administered in the morning.‏‎ (1 link)
  42. 4 months (control group in EF-14 Trial)‏‎ (1 link)
  43. 7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis‏‎ (1 link)
  44. 7.5 months in metastatic breast cancer patients receiving only chemotherapy‏‎ (1 link)
  45. 9.5 months with 100 mg Nexium; 10.9 months with 80 mg Nexium‏‎ (1 link)
  46. At higher doses: delirium and peripheral motor neuropathy; minimal toxicity when alcohol is not consumed‏‎ (1 link)
  47. BCNU alone: median survival of 11 months‏‎ (1 link)
  48. Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain‏‎ (1 link)
  49. Carefully monitored to avoid clinical symptoms of hypothyroidism; includes potential for fatigue if not properly managed‏‎ (1 link)
  50. Chloroquine with BCNU: median survival significantly improved to 25-33 months; recent meta-analysis supports decreased mortality and improved survival time in glioblastoma patients‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"